Provided by Tiger Trade Technology Pte. Ltd.

Phathom Pharmaceuticals

14.58
-0.1200-0.82%
Post-market: 14.58-0.0015-0.01%17:57 EST
Volume:710.94K
Turnover:10.36M
Market Cap:1.04B
PE:-3.84
High:14.85
Open:14.69
Low:14.12
Close:14.70
52wk High:16.27
52wk Low:2.21
Shares:71.14M
Float Shares:51.95M
Volume Ratio:0.84
T/O Rate:1.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8010
EPS(LYR):-5.2920
ROE:-3489.00%
ROA:-42.54%
PB:-2.45
PE(LYR):-2.76

Loading ...

Company Profile

Company Name:
Phathom Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
427
Office Location:
100 Campus Drive,Suite 102,Florham Park,New Jersey,United States
Zip Code:
07932
Fax:
- -
Introduction:
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Directors

Name
Position
Michael F. Cola
Director and Chairman
Steven Basta
President, Chief Executive Officer and Director
Asit Parikh
Director
Frank Karbe
Director
Heidi Kunz
Director
James Topper
Director
Mark Stenhouse
Director
Theodore R. Schroeder
Director

Shareholders

Name
Position
Steven Basta
President, Chief Executive Officer and Director
Azmi Nabulsi
Chief Operating Officer
Molly Henderson
Chief Financial and Business Officer
Robert Breedlove
Principal Accounting Officer
Sanjeev Narula
Chief Financial and Business Officer and Principal Financial Officer